OBIO
Orchestra BioMed Holdings, Inc.
There isn't enough reported data to score OBIO yet.
OBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
OBIO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OBIO PE Valuation
OBIO has no meaningful PE right now: it lost money over the past year.
OBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect OBIO's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.73 | +$1.08 |
| Q2 2026 | -$0.83 | +$0.99 |
| Q1 2026 | -$0.95 | +$0.82 |
| Q4 2025 | -$1.11 | +$0.55 |
| Q3 2025 | -$1.81 | -$0.22 |
| Q2 2025 | -$1.82 | -$0.26 |
| Q1 2025 | -$1.77 | -$0.31 |
| Q4 2024 | -$1.66 | -$0.18 |
OBIO is still losing money, but far less than before: $0.73 per share over the past year, against $1.82 at its worst in mid-2025.
OBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $91K | -89% |
| Q2 2026 | $88K | -89% |
| Q1 2026 | $110K | -87% |
| Q4 2025 | $30.9M | +12120% |
| Q3 2025 | $861K | -13% |
| Q2 2025 | $836K | +7.5% |
| Q1 2025 | $868K | +40% |
| Q4 2024 | $253K | -3.4% |
OBIO's revenue is growing: $91,000 last quarter, down 89% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25600% | -23241 points |
| Q2 2026 | -25405% | -23093 points |
| Q1 2026 | -20069% | -17889 points |
| Q4 2025 | 22% | +6614 points |
| Q3 2025 | -2359% | -704 points |
| Q2 2025 | -2312% | -145 points |
| Q1 2025 | -2180% | +146 points |
| Q4 2024 | -6592% | -1828 points |
OBIO's operating margin was −25600% last quarter, down 23241 points from the same quarter a year ago, near the bottom of its range since 2023.
OBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.9M | -$5.1M |
| Q2 2026 | -$19.6M | -$4M |
| Q1 2026 | -$22.4M | -$5.6M |
| Q4 2025 | -$2.3M | +$11.3M |
| Q3 2025 | -$14.9M | -$1.1M |
| Q2 2025 | -$15.6M | -$5.2M |
| Q1 2025 | -$16.7M | -$3.6M |
| Q4 2024 | -$13.6M | -$2.7M |
OBIO has burned cash in almost every quarter: −$64M over the past year, against −$61M the year before.
OBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +808K shares |
| 1 year | +24% | +12.4M shares |
| 3 years | +83% | +29.4M shares |
| 5 years | +304% | +48.6M shares |
| Available history | +216% | +44.2M shares |
OBIO has 65M diluted shares, up 24% from a year ago.
OBIO Net Leverage
OBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 77.1 | Neutral |
OBIO's weekly RSI is 65 (neutral) and its Stochastic is 77 (neutral).
OBIO PE vs Healthcare Sector
OBIO has no meaningful PE right now: it lost money over the past year.
OBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.83 | 5.5% above |
| 20 week MA | $5.13 | 20% above |
| 50 week MA | $4.55 | 35% above |
| 100 week MA | $4.09 | 50% above |
| 200 week MA | $6.09 | 1% above |
OBIO has climbed back above all five of its weekly moving averages, and it's now 1% above its 200-week average.
OBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.9 | $11.8 | -0.8% |
| 2021 | $11.8 | $9.83 | -17% |
| 2022 | $9.83 | $9.97 | +1.4% |
| 2023 | $9.97 | $9.13 | -8.4% |
| 2024 | $9.13 | $4.40 | -52% |
| 2025 | $4.40 | $4.32 | -1.8% |
| 2026 YTD | $4.32 | $6.15 | +42% |
OBIO has finished three years in a row lower, and it's up 42% so far in 2026.